Floatz logo

Mage-12 Peptide Vaccine

Adult Soft Tissue Sarcoma

National Cancer Institute (NCI)vaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

104 Active assets in the Adult Soft Tissue Sarcoma cohort.

Asset / SponsorPhaseRating
Palbociclib
Brown University
Phase 2BB
FILGRASTIM
University of California, Irvine
Phase 3BB
Inno-206
GI Innovation, Inc.
Phase 3BB
Eloxatin
OHSU Knight Cancer Institute
Phase 2BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

Mage-12 Peptide Vaccine is also rated in:

ocular cancerDormant
CC
Indicative ·
47 / 100
View asset →
bone cancerDormant
CC
Indicative ·
47 / 100
View asset →
uterine corpus sarcomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →